3 VAN DE GRAAFF DRIVE, BURLINGTON, MA
Shareholder votes
Announces Pricing of $60 Million Underwritten Offering of Common Stock
REMAIN-1 Study Shows Revita® Aids Weight Maintenance Post-GLP-1
Changes in Board, Management or Compensation
Announces Second Quarter 2025 Financial Results and Business Updates
News, Underwriting Agreement, Securities Holder Rights or Indentures, Legal Opinion, Material Contracts
Fractyl Health Reveals Data on Rejuva® Preventing Obesity and Type 2 Diabetes
Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(4)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
SEC Staff Correspondence
Correspondence